Biocon signs out-licensing pact with Ajanta to market Semaglutide in 26 countries

Strategic Transactions View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹400.90

prior close

₹404.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.5%-0.2% vs market

Pharmaceuticals peers, median of 154sector-0.5%-0.2% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7-0.5-0.2-0.5-0.2

Next day

-1.3-0.7-0.6-0.9-0.4

-2.5-1.1-1.4-1.7-0.8

-2.4-1.3-1.1-1.7-0.7

-1.9-0.3-1.5-1.0-0.8

-3.2+0.1-3.2-1.0-2.1

-2.3+0.9-3.2-0.7-1.6

15d

-6.1-1.7-4.4-3.8-2.3

-9.4-5.5-3.8-8.3-1.1

-2.3-2.4+0.0-7.6+5.3

-7.7-10.8+3.1-13.6+5.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon has signed an out-licensing agreement with Ajanta Pharma to market Semaglutide, a diabetes drug, across 26 countries. Biocon will supply the drug while Ajanta handles marketing — exclusive in 23 countries and semi-exclusive in 3, covering Africa, Middle East and Central Asia. The deal expands Biocon's GLP-1 portfolio reach via Ajanta's branded generic network in 30 plus countries. CEO Siddharth Mittal called it a strategic step to maximize value of Biocon's peptide investments and broaden affordable access to Semaglutide.

Likely market impact

Positive for Biocon — expands Semaglutide/GLP-1 portfolio reach to 26 emerging markets via Ajanta's network. Likely to drive incremental revenue.